申请人:SmithKline Corporation
公开号:US04192872A1
公开(公告)日:1980-03-11
6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines whose structures have a lower alkyl substituted at the 3 or N-position have potent and often specific anti-Parkinsonism activity by means of their central dopaminergic effect. The lead compound of the series is 6-chloro-3-methyl-1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepi ne as the base or its salts such as the hydrochloride, hydrobromide or methane sulfonate.
结构中在3或N位替代有较低烷基的6-卤代-7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并哌啶具有强大且通常特异的抗帕金森病活性,通过它们的中枢多巴胺能作用。该系列的先导化合物是6-氯-3-甲基-1-苯基-7,8-二羟基-2,3,4,5-四氢-1H-3-苯并哌啶,作为其盐,如盐酸盐、溴化盐或甲磺酸盐。